Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIEOP-BFM ALL 2017 for children and adolescents with acute lymphoblastic leukemia
2016-001935-12Phase 3Active
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Feb 2018
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib and blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoints: Event-free survival from randomization and Overall survival. Started Feb 2018; status: active.
02
Drugs
bortezomibblinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2016-001935-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001935-12.